Transmission of Oncogenic HPV Infection Among Families
Launched by TAMPERE UNIVERSITY HOSPITAL · Jun 16, 2025
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This study is looking at how certain types of human papillomavirus (HPV) that can lead to cancers—like cervical cancer and some head and neck cancers—are passed between family members. Researchers want to learn more about how HPV spreads between sexual partners and from parents to their children. They will also explore how other microbes (tiny organisms like bacteria) might affect how long HPV infections last and how likely they are to cause cancer.
The study will include up to 300 couples from clinics in Finland, along with their children who are over 12 years old. Eligible participants are people who have a long-lasting HPV infection, cervical cancer, or HPV-related head and neck cancer, as well as their partners and children. Those taking part will provide samples from their mouth and private areas themselves, several times over up to five years. They will also fill out questionnaires about their health, habits, and environment. The information gathered will help improve HPV screening and prevention, and may identify new signs that increase cancer risk. This study is not yet enrolling participants, and you need to speak Finnish to take part.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient with colposcopy clinic detected persisting HR-HPV infection
- • Patient with diagnosed cervical cancer
- • Patient with diagnosed OSCC
- • Patients' sexual partners of women or men that are referred to the colposcopy/gynecological oncology/ENT
- • offspring (over 12 years old) of the referred couples
- Exclusion Criteria:
- • Candidate who don't speak Finnish
About Tampere University Hospital
Tampere University Hospital (TAYS) is a leading academic medical center in Finland, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, TAYS integrates cutting-edge medical practices with rigorous scientific investigation, focusing on improving patient outcomes and enhancing treatment modalities across various specialties. The hospital collaborates with a network of researchers, healthcare professionals, and academic institutions to foster a multidisciplinary approach to medical research, ensuring that findings are translated into real-world applications for the benefit of patients and the broader healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kuopio, , Finland
Tampere, , Finland
Patients applied
Trial Officials
Karolina Louvanto, Professor
Principal Investigator
Tampere University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported